-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Company Profile
Oxurion NV – Company Profile
Oxurion NV (Oxurion), formerly ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion’s product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements...
Add to Basket -
Thematic Analysis
Impact of Brazil on the Pharmaceutical Industry – Thematic Intelligence
Brazil Pharmaceutical Market Report Overview Brazil is the largest pharmaceutical market in Central/Southern America and is the 12th largest in the world. Brazil is an untapped market for big pharma manufacturing, with domestic companies dominating the marketed products landscape. The domestic pharmaceutical companies will continue to grow due to favorable policies provided by the Brazilian government to promote domestic production of medicines. Furthermore, over the years, Brazil has elevated its infrastructure, scientific, and technological facilities and has created a sustainable...
-
Sector Analysis
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...
-
Sector Analysis
COVID-19: Contract Pharmaceutical Development and Manufacturing Relationships
This report examines contract manufacturing agreements for vaccines and therapies targeting COVID-19. It reports that there are more than 1,000 vaccines and therapies in development for COVID-19, and 36 vaccines and therapies approved (or granted emergency use authorization) for COVID-19 (as of report publication). At the beginning of the pandemic, slightly more than half of these agreements were for vaccines; this proportion has risen and continues to rise, as several vaccines have proven their safety and efficacy, received approval, and...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Vaccines – Contract Development and Manufacturing Landscape
This expert trend report is a comprehensive look at the contract manufacturing landscape surrounding COVID-19 Vaccine in 2020, including analysis of pipeline drugs, clinical trials, CMO activity, Contract Manufacturing Service Agreements, and funding for manufacturing of COVID-19 Vaccines. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.
-
Sector Analysis
Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.
-
Track & Monitor
PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition
This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.